Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
273.6 CHF | +0.66% | +1.79% | +4.67% |
Jun. 14 | Roche: collaboration agreement in colon cancer | CF |
Jun. 13 | Nkarta, Inc. Appoints George Vratsanos as Board of Directors | CI |
Sales 2024 * | 60.61B 68.07B | Sales 2025 * | 63.99B 71.87B | Capitalization | 200B 225B |
---|---|---|---|---|---|
Net income 2024 * | 13.25B 14.89B | Net income 2025 * | 14.74B 16.56B | EV / Sales 2024 * | 3.54 x |
Net Debt 2024 * | 14.08B 15.82B | Net Debt 2025 * | 9B 10.11B | EV / Sales 2025 * | 3.27 x |
P/E ratio 2024 * |
14.6
x | P/E ratio 2025 * |
13.2
x | Employees | 103,605 |
Yield 2024 * |
3.95% | Yield 2025 * |
4.06% | Free-Float | 88.91% |
Latest transcript on Roche Holding AG
1 day | +0.66% | ||
1 week | +1.79% | ||
Current month | +8.23% | ||
1 month | +11.58% | ||
3 months | +11.58% | ||
6 months | +4.59% | ||
Current year | +4.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
Director/Board Member | 59 | - | |
Director/Board Member | 66 | 95-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
2.06% | 2 M€ | -.--% | - | |
2.06% | 2 M€ | +9.19% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-14 | 273.6 | +0.66% | 30,606 |
24-06-13 | 271.8 | +1.19% | 25,985 |
24-06-12 | 268.6 | +1.05% | 33,856 |
24-06-11 | 265.8 | +0.15% | 42,691 |
24-06-10 | 265.4 | -1.26% | 27,308 |
Delayed Quote Swiss Exchange, June 14, 2024 at 11:30 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.70% | 791B | |
+41.96% | 630B | |
-7.15% | 350B | |
+18.77% | 328B | |
+8.79% | 298B | |
+18.02% | 246B | |
+11.95% | 218B | |
+3.68% | 160B | |
-4.38% | 156B |
- Stock Market
- Equities
- ROG Stock
- RO Stock